ST. LOUIS, May 4 /PRNewswire/ -- Auxeris Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of medicines to treat a broad range of bone diseases, today announced that Jonathan McIntyre, Ph.D., joined the company to support the development of its lead candidates for the prevention and treatment of osteoporosis and bone metastases.
"Jon brings 12 years of drug discovery, development and manufacturing experience to Auxeris. His depth and breadth of experience in large scale protein production of biopharmaceuticals is a significant asset to Auxeris that will help the company become a leader in the development of novel biologic therapies for bone diseases," said Laurent Fischer, M.D., President and CEO of Auxeris.
Prior to joining Auxeris, Dr. McIntyre served for more than three years as Chief Scientist for Monsanto Protein Technologies (MPT). As Chief Scientist, Dr. McIntyre led research, development and quality assurance and employed plant biotechnology and large-scale sterile protein production for biopharmaceutical contract manufacturing. Under Dr. McIntyre's leadership, MPT reduced the timeline to deliver clinical material to clients by 18 months and increased the amount of protein delivered to clients by 25-fold, implemented pharmaceutical quality standards, initiated three co-development programs up to phase III and published extensively on monoclonal antibodies expressed in transgenic corn seed. Dr. McIntyre also played a key role in regulatory strategy with the FDA at Monsanto and G.D. Searle, and held management roles in drug discovery and development. He contributed to the discovery and development of drug candidates to lower LDL cholesterol, increase HDL cholesterol, reduce serum triglycerides and reduce blood pressure. Dr. McIntyre earned his B.S. in Chemistry from Grove City College and his Ph.D. in Biochemistry from the University of Cincinnati College of Medicine. Dr. McIntyre is a member of multiple professional societies including: American Association of Pharmaceutical Scientists, American Chemical Society, Federation of American Societies for Experimental Biology, American Society for Biochemistry and Molecular Biology, American Association for the Advancement of Science.
Auxeris also announced that Dr. Fischer will present today, Tuesday May 4, 2004, during the Biotechnology Industry Organization's BIO Mid-America Venture Forum. The conference will take place May 3-5 at the Chase Park Plaza Hotel in St. Louis.
Auxeris Therapeutics, Inc. ("Auxeris") is a privately-held biopharmaceutical company focused on the development and commercialization of proprietary breakthrough medicines to treat a broad range of bone diseases. The Company's first two products, a novel injectable anti-resorptive to prevent bone metastases and the first oral bone anabolic drug for the treatment of osteoporosis, represent novel treatment approaches and are expected to enter clinical trials in the next eighteen months. Auxeris was founded in 2002 based on technology of Drs. Steven Teitelbaum and Patrick Ross of Washington University School of Medicine and Dr. Gerard Karsenty of Baylor College of Medicine. The company has raised $4.1 million series A from Domain Associates of Princeton, NJ and RiverVest Ventures Partners of St. Louis, MO. For more information, visit the company website at http://www.auxeris.com/.
Auxeris Therapeutics Inc.
CONTACT: media, Virginia Amann of Atkins + Associates, +1-608-274-6046,email@example.com, for Auxeris Therapeutics Inc.; or Laurent Fischer, MD,President & CEO of Auxeris Therapeutics Inc., +1-314-633-1881,firstname.lastname@example.org